Search

Author/Creator Chand, Vikram K.

1. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. (November 2017)

Authors:
Horn, Leora; Gettinger, Scott; Camidge, D. Ross; Smit, Egbert F.; Janjigian, Yelena Y.; Miller, Vincent A.; Pao, William; Freiwald, Matthias; Fan, Jean; Wang, Bushi; Chand, Vikram K.; Groen, Harry J.M.
Journal:
Lung cancer
Issue:
Volume 113(2017)
Page Start:
51
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Issue 16 (14th June 2013)

Authors:
Kwak, Eunice L.; Shapiro, Geoffrey I.; Cohen, Seth M.; Becerra, Carlos R.; Lenz, Heinz‐Josef; Cheng, Wen‐Fang; Su, Wu-Chou; Robohn, Meghan; Le Maulf, Florence; Lobmeyer, Maximilian T.; Chand, Vikram K.; Iafrate, A. John
Journal:
Cancer
Issue:
Volume 119:Issue 16(2013)
Page Start:
3043
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Issue 16 (14th June 2013)

Authors:
Kwak, Eunice L.; Shapiro, Geoffrey I.; Cohen, Seth M.; Becerra, Carlos R.; Lenz, Heinz‐Josef; Cheng, Wen‐Fang; Su, Wu-Chou; Robohn, Meghan; Le Maulf, Florence; Lobmeyer, Maximilian T.; Chand, Vikram K.; Iafrate, A. John
Journal:
Cancer
Issue:
Volume 119:Issue 16(2013)
Page Start:
3043
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Issue 1 (April 2015)

Authors:
De Grève, Jacques; Moran, Teresa; Graas, Marie-Pascale; Galdermans, Daniella; Vuylsteke, Peter; Canon, Jean-Luc; Schallier, Denis; Decoster, Lore; Teugels, Erik; Massey, Dan; Chand, Vikram K.; Vansteenkiste, Johan
Journal:
Lung cancer
Issue:
Volume 88:Issue 1(2015:Apr.)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Issue 1 (April 2015)

Authors:
De Grève, Jacques; Moran, Teresa; Graas, Marie-Pascale; Galdermans, Daniella; Vuylsteke, Peter; Canon, Jean-Luc; Schallier, Denis; Decoster, Lore; Teugels, Erik; Massey, Dan; Chand, Vikram K.; Vansteenkiste, Johan
Journal:
Lung cancer
Issue:
Volume 88:Issue 1(2015:Apr.)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search